JPH0571566B2 - - Google Patents
Info
- Publication number
- JPH0571566B2 JPH0571566B2 JP58236994A JP23699483A JPH0571566B2 JP H0571566 B2 JPH0571566 B2 JP H0571566B2 JP 58236994 A JP58236994 A JP 58236994A JP 23699483 A JP23699483 A JP 23699483A JP H0571566 B2 JPH0571566 B2 JP H0571566B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- aqueous solution
- present
- long
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 230000007774 longterm Effects 0.000 claims description 7
- 238000000465 moulding Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 description 13
- 108010050904 Interferons Proteins 0.000 description 13
- 229940079322 interferon Drugs 0.000 description 11
- 102000006992 Interferon-alpha Human genes 0.000 description 10
- 108010047761 Interferon-alpha Proteins 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108010045569 atelocollagen Proteins 0.000 description 8
- 238000000748 compression moulding Methods 0.000 description 7
- 239000003405 delayed action preparation Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000005187 foaming Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 etc. Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004386 diacrylate group Chemical group 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23699483A JPS60126217A (ja) | 1983-12-14 | 1983-12-14 | 長期徐放性製剤 |
| EP19840112310 EP0139286B1 (en) | 1983-10-14 | 1984-10-12 | Prolonged sustained-release preparations |
| DE8484112310T DE3484951D1 (de) | 1983-10-14 | 1984-10-12 | Verlaengerte praeparate mit verzoegerter abgabe. |
| US06/846,193 US4774091A (en) | 1983-10-14 | 1986-03-31 | Long-term sustained-release preparation |
| US07/187,443 US5021241A (en) | 1983-10-14 | 1988-04-28 | Long-term sustained-release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23699483A JPS60126217A (ja) | 1983-12-14 | 1983-12-14 | 長期徐放性製剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5023778A Division JPH0694418B2 (ja) | 1993-01-18 | 1993-01-18 | 長期徐放性製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60126217A JPS60126217A (ja) | 1985-07-05 |
| JPH0571566B2 true JPH0571566B2 (pt) | 1993-10-07 |
Family
ID=17008809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23699483A Granted JPS60126217A (ja) | 1983-10-14 | 1983-12-14 | 長期徐放性製剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60126217A (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0657658B2 (ja) * | 1985-04-11 | 1994-08-03 | 住友製薬株式会社 | 徐放性製剤 |
| JPS60174726A (ja) * | 1984-02-21 | 1985-09-09 | Nippon Shinyaku Co Ltd | 注射用医薬組成物 |
| US4888366A (en) * | 1984-10-24 | 1989-12-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
| JPH0694418B2 (ja) * | 1993-01-18 | 1994-11-24 | 住友製薬株式会社 | 長期徐放性製剤 |
| CN1230205C (zh) * | 1995-07-03 | 2005-12-07 | 株式会社高研 | 基因制剂 |
| CA2217134A1 (en) * | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56122317A (en) * | 1980-02-29 | 1981-09-25 | Koken:Kk | Drug transporting material and its preparation |
| JPS5729448A (en) * | 1980-07-29 | 1982-02-17 | Inoue Mtp Kk | Integrally bonded structure of flexible laminate |
| JPS57116008A (en) * | 1981-01-13 | 1982-07-19 | Mitsui Toatsu Chem Inc | Novel formed drug |
| JPS5865211A (ja) * | 1981-10-13 | 1983-04-18 | Mitsui Toatsu Chem Inc | 徐放性成形制ガン剤 |
| JPS58140011A (ja) * | 1982-02-12 | 1983-08-19 | Unitika Ltd | 抗癌性物質徐放性塞栓剤 |
| JPS58174330A (ja) * | 1982-04-07 | 1983-10-13 | Asahi Chem Ind Co Ltd | ガン壊死因子の安定化法 |
-
1983
- 1983-12-14 JP JP23699483A patent/JPS60126217A/ja active Granted
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56122317A (en) * | 1980-02-29 | 1981-09-25 | Koken:Kk | Drug transporting material and its preparation |
| JPS5729448A (en) * | 1980-07-29 | 1982-02-17 | Inoue Mtp Kk | Integrally bonded structure of flexible laminate |
| JPS57116008A (en) * | 1981-01-13 | 1982-07-19 | Mitsui Toatsu Chem Inc | Novel formed drug |
| JPS5865211A (ja) * | 1981-10-13 | 1983-04-18 | Mitsui Toatsu Chem Inc | 徐放性成形制ガン剤 |
| JPS58140011A (ja) * | 1982-02-12 | 1983-08-19 | Unitika Ltd | 抗癌性物質徐放性塞栓剤 |
| JPS58174330A (ja) * | 1982-04-07 | 1983-10-13 | Asahi Chem Ind Co Ltd | ガン壊死因子の安定化法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS60126217A (ja) | 1985-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5081156A (en) | Sustained-release preparation | |
| EP0139286B1 (en) | Prolonged sustained-release preparations | |
| ES2245827T3 (es) | Preparaciones de liberacion controlada con una estructura de capas multiples. | |
| KR100236771B1 (ko) | 히아루론산을 이용한 약물의 서방성 미세입자 제형 | |
| CA2317411C (en) | Controlled release delivery of peptide or protein | |
| US4774091A (en) | Long-term sustained-release preparation | |
| EP0230647B1 (en) | Method for producing a sustained release formulation | |
| EP0138216B1 (en) | Sustained-release ifn preparation for parenteral administration | |
| US7976847B2 (en) | Controlled release CGRP delivery composition for cardiovascular and renal indications | |
| ES2294814T3 (es) | Geles de liberacion retardada y sostenida. | |
| LV10041B (en) | Microcapsules and method of producing thereof | |
| JPH03163032A (ja) | 脳内投与用徐放性製剤 | |
| JPH0725688B2 (ja) | Ｃｓｆ徐放性製剤 | |
| JPH0571566B2 (pt) | ||
| JPH1045616A (ja) | 注射用徐放性製剤 | |
| JPS61236729A (ja) | 徐放性製剤 | |
| JPH0512328B2 (pt) | ||
| JPH0372046B2 (pt) | ||
| KR100329336B1 (ko) | 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형 | |
| JPH0439337B2 (pt) | ||
| JPH0759522B2 (ja) | 徐放性製剤の製造法 | |
| RU2809091C1 (ru) | Подкожный биодеградируемый имплантат для отсроченной гемостимуляции онкологических больных | |
| JPH02710A (ja) | コントロールリリース製剤 | |
| JP2006096751A (ja) | インターロイキン−１１徐放性医薬組成物 | |
| JPH05246879A (ja) | 長期徐放性製剤 |